NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $55.20 -1.02 (-1.81%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$55.28 +0.08 (+0.14%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BMRN alerts:Sign Up Key Stats Today's Range$54.76▼$56.6050-Day Range$55.20▼$70.2452-Week Range$49.26▼$70.98Volume2.08 million shsAverage Volume2.14 million shsMarket Capitalization$10.69 billionP/E Ratio149.19Dividend YieldN/APrice Target$89.17Consensus RatingModerate Buy Company Overview BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy. Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates. BioMarin has also developed Roctavian, a gene therapy for adults with severe hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets. The company sells its therapies through specialty healthcare and commercial distribution networks and continues to invest in treatments for rare diseases. Alexander Hardy has served as BioMarin’s president and chief executive officer since 2023.AI Generated. May Contain Errors. Read More BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreBMRN MarketRank™: BioMarin Pharmaceutical scored higher than 85% of companies evaluated by MarketBeat, and ranked 60th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 15 buy ratings, 7 hold ratings, and 1 sell rating.Upside PotentialBioMarin Pharmaceutical has a consensus price target of $89.17, representing about 61.5% upside from its current price of $55.20.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth32.20% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 32.20% in the coming year, from $4.10 to $5.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 149.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.85.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 149.19, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.55.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.40. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.24% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 5.53.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 2.01%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.38 News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for BioMarin Pharmaceutical this week, compared to 8 articles on an average week.Search InterestOnly 17 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders0.68% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMRN Stock News HeadlinesBioMarin Appoints Cara Bauer as Chief People OfficerOctober 5 at 4:05 PM | prnewswire.comBioMarin Pharmaceutical consensus price target increases 11.35% to MX$1,755.39October 3, 2026 | msn.comWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure investment in Finland. Cerebras followed with plans for a 165 MW data center worth up to 1.7 billion euros. One small Nasdaq-listed company built its Nordic footprint before this wave hit, with up to 190 MW of capacity approaching ready-for-service status in 2027 to early 2028. Recent long-term data center deals have valued capacity at 1.7 to 2 million dollars per MW annually. See why this overlooked company could be next in the AI infrastructure spotlight.October 8 at 1:00 AM | The Tomorrow Investor (Ad)BioMarin Says 5-Year Data Shows Durable Efficacy of Pombiliti Plus Opfolda in Pompe DiseaseOctober 2, 2026 | finance.yahoo.comBioMarin Reports 5-Year Motor, Lung Data For Pompe Disease TherapyOctober 2, 2026 | rttnews.comBioMarin Adds Five-Year Evidence For POMBILITI + OPFOLDA; Stock DownOctober 2, 2026 | rttnews.comBioMarin reports five-year Pompe disease data showing durable motor functionOctober 2, 2026 | cnbc.comBioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual CongressOctober 2, 2026 | prnewswire.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $59.43 on January 1st, 2026. Since then, BMRN stock has decreased by 7.1% and is now trading at $55.20. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts' consensus estimates of $0.95 by $0.25. The firm's revenue for the quarter was up 20.0% on a year-over-year basis. Read the conference call transcript. Who are BioMarin Pharmaceutical's major shareholders? Top institutional shareholders of BioMarin Pharmaceutical include First Financial Bank Trust Division (0.02%) and Miller Global Investments LLC. Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Charles Greg Guyer, Brian Mueller, George Eric Davis, Gregory R Friberg, Cristin Hubbard and Erin Burkhart. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), Broadcom (AVGO). Company Calendar Last Earnings8/06/2026Today10/07/2026Next Earnings (Estimated)10/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, BMRN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CIK1048477 Webwww.biomarin.com Phone(415) 506-6700Fax415-382-7889Employees3,221Year Founded1997Price Target and Rating Average Price Target for BioMarin Pharmaceutical$89.17 High Price Target$124.00 Low Price Target$60.00 Potential Upside/Downside+61.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$0.37 Trailing P/E Ratio149.19 Forward P/E Ratio13.46 P/E Growth0.4Net Income$348.90 million Net Margins2.14% Pretax Margin4.38% Return on Equity5.32% Return on Assets3.69% Debt Debt-to-Equity Ratio0.56 Current Ratio2.39 Quick Ratio1.32 Sales & Book Value Annual Sales$3.22 billion Price / Sales3.32 Cash Flow$2.80 per share Price / Cash Flow19.70 Book Value$31.68 per share Price / Book1.74Miscellaneous Outstanding Shares193,570,000Free Float192,258,000Market Cap$10.69 billion OptionableOptionable Beta0.22 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BMRN) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersElon’s FINAL Warning? [US Dollar Collapse]On April 25, 2023, Elon Musk issued a stark warning about the future of the US dollar. A former Wall Street...International Living | SponsoredA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredWhat Could Change After November 3rd?Democrats are favored to take the House on November 3rd, needing just five seats to flip the chamber. The last...USA Capital Gold | Sponsored“Whoever wins AI, wins”Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure inve...The Tomorrow Investor | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRN Stock Alerts